Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18820954 | MEDICAL ITEM RESUPPLY ENGINE AND ENGAGEMENT CONTROLLER | August 2024 | March 2026 | Allow | 18 | 1 | 0 | No | No |
| 18733999 | SECURE VERIFICATION OF MEDICAL STATUS USING A CONTACTLESS CARD | June 2024 | July 2025 | Allow | 14 | 1 | 0 | No | No |
| 18703136 | DETERMINING A MEASURE OF SUBJECT SIMILARITY | April 2024 | March 2026 | Abandon | 23 | 1 | 0 | No | No |
| 18337346 | INTENT-BASED CLUSTERING OF MEDICAL INFORMATION | June 2023 | May 2025 | Abandon | 23 | 2 | 0 | Yes | No |
| 18137692 | METHODS AND SYSTEMS FOR REDISTRIBUTING MEDICATION | April 2023 | October 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18133623 | SYSTEMS AND METHODS FOR COORDINATING CARE VIA AN INTEGRATED SOCIAL DETERMINANTS OF HEALTH (SDOH) PLATFORM | April 2023 | June 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18132134 | SYSTEMS AND METHODS FOR USING ELLIPTICAL MACHINE TO PERFORM CARDIOVASCULAR REHABILITATION | April 2023 | January 2026 | Abandon | 33 | 3 | 1 | No | No |
| 18114368 | TRANSFORMER-BASED NEURAL NETWORK FOR JOINTLY PREDICTING LENGTH OF STAY AND CRITICAL INTERVENTIONS FOR PATIENTS | February 2023 | November 2025 | Allow | 33 | 2 | 0 | No | No |
| 18168461 | SYSTEMS AND METHODS FOR PATIENT RETENTION IN NETWORK THROUGH REFERRAL ANALYTICS | February 2023 | September 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 17991038 | DIGITAL HEALTH PLATFORM FOR ARTIFICIAL INTELLIGENCE BASED SEIZURE MANAGEMENT | November 2022 | October 2025 | Abandon | 45 | 2 | 0 | Yes | No |
| 17921894 | SLEEP SCREENING DATA MANAGEMENT SYSTEM AND SLEEP SCREENER MANAGEMENT SYSTEM | October 2022 | September 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17904853 | HEALTH AND SAFETY MANAGEMENT SYSTEM | August 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17893586 | BLOOD TRANSFUSION TRACKING AND DECISION SUPPORT | August 2022 | November 2025 | Abandon | 39 | 2 | 0 | Yes | No |
| 17880765 | STRUCTURED SUPPORT OF CLINICAL HEALTHCARE PROFESSIONALS | August 2022 | April 2025 | Abandon | 32 | 4 | 0 | Yes | No |
| 17864631 | Healthcare Occupational Outcomes Navigation Engine | July 2022 | September 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17725594 | SYSTEMS OF ENHANCED DISTRIBUTION OF PHARMACEUTICALS IN LONG-TERM CARE FACILITIES | April 2022 | April 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17685224 | CARE MANAGEMENT SYSTEM | March 2022 | December 2025 | Abandon | 46 | 4 | 0 | Yes | No |
| 17684878 | METHOD OF MAPPING AND MACHINE LEARNING FOR PATIENT-HEALTHCARE ENCOUNTERS TO PREDICT PATIENT HEALTH AND DETERMINE TREATMENT OPTIONS | March 2022 | February 2026 | Abandon | 47 | 3 | 0 | No | No |
| 17683012 | SENSOR-BASED SYSTEM AND METHOD FOR DISPATCH AND ALLOCATION OF MEDICAL DEVICES AND THE LIKE | February 2022 | March 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17519067 | VACCINATION RECORD | November 2021 | December 2024 | Abandon | 37 | 2 | 0 | Yes | No |
| 17607276 | HEALTH RECORD SYSTEM | October 2021 | September 2025 | Abandon | 46 | 3 | 0 | Yes | No |
| 17512205 | AIML TO MONITOR CLINICAL PROTOCOL DEVIATIONS | October 2021 | April 2025 | Abandon | 41 | 2 | 0 | Yes | No |
| 17451729 | SEIZURE PREDICTION MACHINE LEARNING MODELS | October 2021 | March 2025 | Allow | 41 | 3 | 0 | Yes | No |
| 17498960 | Nutrition and Fitness System | October 2021 | May 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17498915 | SYSTEMS AND METHODS FOR EARLY IDENTIFICATION OF A TOTAL LOSS VEHICLE | October 2021 | November 2025 | Abandon | 49 | 5 | 0 | Yes | No |
| 17495048 | DOSAGE REGIMEN SUPPORTING APPARATUS AND DOSAGE REGIMEN SUPPORTING SYSTEM | October 2021 | September 2025 | Abandon | 47 | 4 | 0 | No | No |
| 17493159 | METHODS AND SYSTEMS FOR PRIORITIZING USER SYMPTOM COMPLAINT INPUTS | October 2021 | February 2026 | Allow | 52 | 3 | 0 | Yes | No |
| 17382724 | Healthcare Product Recall Management System | July 2021 | October 2025 | Abandon | 51 | 4 | 0 | Yes | No |
| 17357737 | Telehealth System and Method | June 2021 | December 2024 | Abandon | 42 | 3 | 0 | Yes | No |
| 17344523 | INTEGRATED, MOLECULAR, OMICS, IMMUNOTHERAPY, METABOLIC, EPIGENETIC, AND CLINICAL DATABASE | June 2021 | November 2025 | Abandon | 54 | 7 | 0 | Yes | No |
| 17316571 | PATIENT DATA MANAGEMENT SYSTEMS AND CONVERSATIONAL INTERACTION METHODS | May 2021 | September 2024 | Allow | 41 | 3 | 0 | Yes | No |
| 17213099 | SYSTEMS AND METHODS FOR EXTRACTION OF CLINICAL KNOWLEDGE WITH REIMBURSEMENT POTENTIAL | March 2021 | May 2025 | Abandon | 50 | 4 | 0 | Yes | No |
| 17274052 | SYSTEM TO PROVIDE SHARED DECISION MAKING FOR PATIENT TREATMENT OPTIONS | March 2021 | March 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17180309 | GLUCOSE LEVEL MANAGEMENT BASED ON FAT CONTENT OF MEALS | February 2021 | March 2025 | Allow | 49 | 4 | 0 | Yes | No |
| 16953183 | METHODS AND SYSTEMS FOR MANAGING DISTRIBUTION AND TREATMENT OF A FOOD ALLERGY ORAL IMMUNOTHERAPY DRUG | November 2020 | March 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17025129 | HEALTH MANAGEMENT SYSTEM WITH MULTIDIMENSIONAL PERFORMANCE REPRESENTATION | September 2020 | December 2024 | Abandon | 51 | 5 | 0 | Yes | No |
| 16985609 | METHODS AND SYSTEMS FOR PROVIDING IMPROVED MECHANISM FOR UPDATING HEALTHCARE INFORMATION SYSTEMS | August 2020 | July 2024 | Allow | 47 | 4 | 0 | Yes | No |
| 16926863 | DIGITAL TWIN MANAGER | July 2020 | February 2025 | Allow | 55 | 5 | 0 | Yes | No |
| 16860659 | Monitoring Patient Compliance with a Dosage Regimen | April 2020 | February 2026 | Abandon | 60 | 5 | 1 | Yes | No |
| 16780448 | AUTOMATED CLINICAL INDICATOR RECOGNITION WITH NATURAL LANGUAGE PROCESSING | February 2020 | December 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16702113 | SYSTEMS AND METHODS FOR GUIDELINE CONCORDANCE | December 2019 | July 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16663656 | MAINTENANCE NOTIFICATION FOR MEDICAL DEVICES | October 2019 | April 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16407900 | COMPUTING ARCHITECTURE FOR ASSURING THE PROVENANCE OF MEDICATION THERAPY RELATED PARAMETERS, AND RELATED SYSTEMS, METHODS AND DEVICES | May 2019 | October 2025 | Allow | 60 | 8 | 0 | Yes | No |
| 16173027 | Apparatus and Method for Care Plan Generation | October 2018 | April 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 15536813 | AUTOMATED DERIVATION OF QUALITY ASSURANCE RULES | June 2017 | November 2025 | Abandon | 60 | 6 | 0 | No | Yes |
| 14218542 | SYSTEM AND METHOD FOR COMMUNICATING WITH A DIALYSIS MACHINE THROUGH A NETWORK | March 2014 | August 2018 | Allow | 53 | 5 | 0 | Yes | No |
| 13736340 | PREPAID CARD FOR SERVICES RELATED TO PERSONAL HEALTH RECORDS | January 2013 | April 2017 | Allow | 52 | 7 | 0 | No | Yes |
| 13705327 | EVIDENCE-BASED HEALTHCARE INFORMATION MANAGEMENT PROTOCOLS | December 2012 | July 2019 | Allow | 60 | 8 | 0 | Yes | No |
| 12675979 | PRECLINICAL TIME OF FLIGHT IMAGING | March 2010 | January 2016 | Allow | 60 | 6 | 0 | Yes | No |
| 12710423 | METHOD FOR THE NOISE REDUCTION OF CT IMAGE DATA AND IMAGE PROCESSING SYSTEM | February 2010 | September 2013 | Allow | 43 | 2 | 0 | Yes | No |
| 11577681 | SYSTEM AND METHOD FOR ASSESSING DATA QUALITY DURING CLINICAL TRIALS | December 2007 | September 2013 | Allow | 60 | 4 | 0 | Yes | No |
| 11678266 | SELF-DESCRIBING DATA FRAMEWORK | February 2007 | August 2013 | Allow | 60 | 4 | 0 | Yes | No |
| 11522493 | Treatment limiter | September 2006 | June 2015 | Allow | 60 | 7 | 0 | Yes | Yes |
| 10756010 | METHOD FOR GENERATING MEDICAL INTELLIGENCE FROM PATIENT-SPECIFIC DATA | January 2004 | December 2010 | Allow | 60 | 5 | 0 | No | Yes |
| 10045649 | SYSTEM AND METHOD FOR ARRANGING SHIPMENT AND INSURANCE FOR AN ITEM | November 2001 | March 2017 | Allow | 60 | 16 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAPILLO, KRISTINE K.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 37.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner RAPILLO, KRISTINE K works in Art Unit 3682 and has examined 36 patent applications in our dataset. With an allowance rate of 47.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 52 months.
Examiner RAPILLO, KRISTINE K's allowance rate of 47.2% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAPILLO, KRISTINE K receive 4.81 office actions before reaching final disposition. This places the examiner in the 99% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by RAPILLO, KRISTINE K is 52 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +16.7% benefit to allowance rate for applications examined by RAPILLO, KRISTINE K. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 9.2% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.5% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 44.4% of appeals filed. This is in the 10% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 55.6% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.